Sixteen weeks of treatment with clarithromycin (CLARI) alone displayed significant bactericidal activity against Mycobacterium avium complex infection in beige mice. Only two combined regimens, CLARI combined with an initial 4 or 8 weeks of amikacin (AMIKA), displayed activity greater than that displayed by CLARI alone. Four other combined regimens, CLARI combined with ethambutol (EMB), rifabutin (RBT), or both EMB and RBT during the entire 16 weeks of treatment or with AMIKA administered in an initial 2-week course showed bactericidal activity not significantly greater than that of CLARI alone. After 16 weeks of treatment, CLARI-resistant mutants were isolated from the majority of mice that had been treated with CLARI alone, CLARI-RBT, CLARI-EMB, or CLARI-EMB-RBT, as was the case for untreated controls, but the frequencies of occurrence of mutants were significantly greater in the groups treated with these combinations or CLARI alone. On the other hand, no CLARI-resistant mutants were isolated from the mice that had been treated with the combination of CLARI plus an initial 4 or 8 weeks of AMIKA and were isolated from only a tiny proportion of mice that had been treated with CLARI plus an initial 2 weeks of AMIKA. Therefore, only treatment with CLARI combined with an initial 4 or 8 weeks of AMIKA but not combined with RBT or EMB or both, could enhance the activity of the drug treatment and prevent the selection of CLARI-resistant mutants.
Disseminated Mycobacterium avium complex infection is common among patients with AIDS (14) , and these organisms are far less susceptible than Mycobacterium tuberculosis to antimicrobial agents. Although new macrolides such as clarithromycin (CLARI) (2) (3) (4) (5) and azithromycin (19) have recently been demonstrated to be effective in the treatment of disseminated M. avium complex infection in AIDS patients, work performed with the M. avium complex-infected beige mouse model has shown that the list of antimicrobial agents active against M. avium in vivo is rather short. In addition to the two macrolides, only amikacin (AMIKA) displayed definite bactericidal activity, which was slightly weaker than or similar to that of CLARI, whereas ethambutol (EMB) displayed only bacteriostatic or, at best, marginally bactericidal activity (10) . Despite the report that rifabutin (RBT) was capable of preventing M. avium complex infection in AIDS patients (15) , all major rifamycin derivatives administered to mice at dosages equivalent to the maximal clinically tolerated dosages were found to be inactive against the strain of M. avium tested (10) . Moreover, sparfloxacin, which is by far the most active fluoroquinolone against M. tuberculosis (13) , exhibited only a very weak bacteriostatic effect in beige mice (10) . The in vitro synergistic effects against the M. avium complex which have frequently been observed with various EMB-containing combinations (6, 8, 20) have not been confirmed in beige mice. On the other hand, the fact that selection of CLARI-resistant mutants was successfully prevented by 12 weeks of treatment with the combination CLARI-AMIKA, although not by the combination CLARI-minocycline, was encouraging (10) .
Because AMIKA must be administered by injection and because its use has been associated with ototoxicity and nephrotoxicity, administration of this drug has usually been limited to 8 weeks. In the present study, to examine the efficacy of treatment with AMIKA as a function of the duration of its administration, we compared combinations of CLARI plus AMIKA administered for initial periods of 2, 4, or 8 weeks, with an emphasis on the emergence of CLARI-resistant mutants in the beige mouse model. In addition, we also tested the efficacies of the combinations CLARI-RBT, CLARI-EMB, and CLARI-EMB-RBT.
MATERIALS AND METHODS
Mice. Female beige (C57BL/6J bg j /bg j ) mice (ages, 4 to 6 weeks; weights, 14 to 18 g) were purchased from Jackson Laboratory, Bar Harbor, Maine. Before infection with the M. avium complex, the mice were housed in our animal facility for an additional 4 weeks, until their body weights reached 18 to 20 g.
M. avium complex. Strain 101 was obtained from the laboratory of L. S. Young, San Francisco, Calif., and was maintained in our laboratory by regular passage through beige mice. The MICs of CLARI, AMIKA, RBT, and EMB for strain 101, determined on 5% oleic acid-albumin-dextrose-catalase (OADC)-enriched Mueller-Hinton agar medium (16) , are, respectively, 1, 16, 2, and 16 g/ml; the MIC of CLARI on 10% OADC-enriched 7H11 agar is 16 g/ml. To prepare the inoculum, about 300 transparent colonies were collected from 10% OADCenriched 7H11 agar and were subcultured in 100 ml of Dubos broth (Diagnostic Pasteur, Paris, France) at 37ЊC for 7 days. The turbidity of the resulting suspension was adjusted with normal saline to match that of a standard suspension of Mycobacterium bovis BCG (1 mg/ml) and was further diluted fivefold. The final suspension contained 1.03 ϫ 10 7 CFU/ml, as determined by plating five appropriate dilutions onto 10% OADC-enriched 7H11 agar.
Antimicrobial agents. The following compounds were generously provided by their manufacturers: CLARI, Abbott Laboratories, North Chicago, Ill.; RBT, Farmitalia-Carlo Erba, Rueil, France; AMIKA, Bristol-Myers Squibb, Paris, France; and EMB, Lederle, Oullins, France. All agents except AMIKA were suspended in 0.05% agar in distilled water at the desired concentrations; the suspensions were prepared weekly and were stored at 4ЊC.
Infection of mice. One hundred eighty-four beige mice were each inoculated intravenously with 0.5 ml of the bacterial suspension, which contained 5.02 ϫ 10 6 CFU. Fifteen mice were held as uninfected controls.
Chemotherapy. Ten inoculated mice each were sacrificed on days 1 (D1), 14 (2 weeks), and 28 (4 weeks) after infection for enumeration of the CFU in the spleens and lungs. At 4 weeks the remaining mice were allocated randomly to an untreated control group (71 mice) and seven treated groups of 10 mice each. All drugs except AMIKA were administered six times weekly by esophageal cannula; AMIKA was injected subcutaneously. Dosages were selected to provide either peak concentrations in serum or areas under the concentration-time curve in the mice that were comparable to those achievable in humans or because the dosages had been used by other investigators; the dosages were as follows: CLARI, 200 mg/kg of body weight (11) ; RBT, 10 mg/kg (12) ; AMIKA, 100 mg/kg (7) ; and EMB, 125 mg/kg (17) . The duration of treatment with all drugs except AMIKA was 16 weeks; that with AMIKA, was for the initial 2, 4, or 8 weeks, referred to as AMIKA (2 weeks), AMIKA (4 weeks), or AMIKA (8 weeks), respectively.
Assessment of results. Ten untreated control mice were sacrificed after 11 weeks of treatment, and 10 more were sacrificed after 16 weeks. At the end of the 20th week, all surviving mice from both untreated control and treated groups were sacrificed. To avoid carryover of drugs in the organs, treated mice were sacrificed 72 h after administration of the last dose. To assess the severity of the infection and the effectiveness of the treatments, mortality, spleen weights, numbers of CFU in the spleens and lungs, and numbers of CFU of CLARI-resistant mutants in the spleens were compared between the groups.
Enumeration of total CFU. At sacrifice or autopsy, the organs were removed aseptically and were homogenized, and each resulting organ suspension was made up to 3.5 ml. At least four serial 10-fold dilutions of each suspension were plated in duplicate onto 10% OADC-enriched 7H11 agar. The results of the cultures were recorded after incubation at 37ЊC for 2 weeks. A bactericidal effect was defined as a significant decrease in the mean number of CFU in the treated group from the pretreatment value, i.e., the values obtained from control mice sacrificed at 4 weeks.
Enumeration of CLARI-resistant mutants. CLARI-resistant mutants were enumerated in the spleen suspensions from untreated control mice sacrificed at 4, 11, 16, and 20 weeks and from all treated mice sacrificed at 20 weeks. On each occasion, in addition to enumeration of the total number of CFU, the spleen suspensions left undiluted and diluted 10 Ϫ1 were also plated, in quadruplicate, onto 10% OADC-enriched 7H11 agar containing CLARI at a concentration of 64 g/ml. Because on 7H11 agar the CLARI MICs at which 90% of strains tested are inhibited are 8 g/ml for the M. avium complex (16) and 16 g/ml for strain 101, a CLARI-resistant mutant was defined as an organism that multiplied on 7H11 agar containing CLARI at 64 g/ml (9, 10), and the lower limit of detectability per organ was 10 0.94 , corresponding to a single colony appearing on four quadrants of medium which had been plated with 0.1 ml of the undiluted suspension. The frequency of CLARI-resistant mutants in the bacterial population was defined as the ratio between the number of CFU of CLARI-resistant mutants and that of total CFU. Statistical analysis. Results were analyzed by the Student t test and Fisher's exact probability calculation. Differences were considered significant at the 95% level of confidence.
RESULTS

Mortality of mice.
During the first 4 weeks after inoculation, excluding the 20 mice sacrificed at D1 or 2 weeks, 13 (7.9%) of the 164 inoculated mice died. Among the 71 mice allocated to the untreated control group at 4 weeks, 20 were sacrificed at 11 or 16 weeks, and 29 (56.9%) of the remaining 51 mice died before 20 weeks. Significantly fewer (5 [7.1%]) of the 70 treated mice died before 20 weeks (P Ͻ 0.01). Thus, treatment with the CLARI-containing regimens significantly reduced the mortality of beige mice from disseminated M. avium infection.
Spleen enlargement. Five uninfected control mice were each sacrificed on D1 and 4 and 20 weeks during the experiment. As shown in Fig. 1 , the mean spleen weights of mice sacrificed at 20 weeks (108 Ϯ 11 mg; column 8 of Fig. 1 ) were only slightly greater than those of mice sacrificed at 4 weeks (P Ͻ 0.01), apparently reflecting the growth of the mice, because the mean body weights of the mice increased from 19.1 Ϯ 1.0 g at D1 to 25.2 Ϯ 1.0 g at 20 weeks (P Ͻ 0.01), but the ratio of the spleen weight to body weight at 20 weeks remained the same (about 0.4%) as that at 4 weeks.
As also portrayed in Fig. 1 , the spleens of untreated control mice enlarged dramatically during the first 2 weeks after inoculation (column 3 versus column 2), slightly increased afterward, and reached the peak at 16 weeks (column 7); this was followed by a decrease in the mean spleen weight by 20 weeks (column 9), perhaps because 12 seriously ill control mice died between 16 and 20 weeks.
Treatment with the CLARI-containing regimens for 16 weeks substantially ameliorated the splenomegaly of beige mice that resulted from disseminated M. avium infection, as shown by the fact that the mean spleen weight for mice from all treated groups (Fig. 1, columns 10 to 16 ) was significantly lower than the pretreatment value ( Fig. 1 , column 5) (P Ͻ 0.01). Among the treated groups, the mean spleen weight for mice that had been treated with CLARI plus an initial 8 weeks of AMIKA (column 13) was significantly lower than that for mice that had been treated with all of the other regimens (P Ͻ 0.01); treatment with none of the other combined regimens yielded a mean spleen weight significantly lower than that for mice treated with CLARI alone (column 10).
Enumeration of CFU in spleens and lungs. As shown in Table 1 , the number of CFU in the spleens and lungs of the untreated control mice increased progressively to 16 weeks, after which there was no further increase. The mean number of CFU increased by more than 2 orders of magnitude between D1 and 4 weeks and by 2 to 3 orders of magnitude between 4 and 16 weeks, suggesting that the multiplication of the organisms was more rapid early in the disease process, slowing thereafter, perhaps as the result of an immune response.
After 16 weeks of treatment, the mean number of CFU in all treated groups was significantly less (P Ͻ 0.01) than the pretreatment values (Table 1) ; thus, all of the regimens studied displayed a certain degree of bactericidal activity against the M. avium complex. Of all of the CLARI-containing combined regimens, only CLARI-AMIKA (4 weeks) and CLARI-AMIKA (8 weeks) yielded mean numbers of CFU in both the spleens and lungs less than those among the mice treated with CLARI alone. In addition, as shown in Table 1 , the mean numbers of CFU were inversely related to the duration of initial treatment with AMIKA; the value in the spleens of mice treated with CLARI-AMIKA (8 weeks) was significantly less than that in the spleens of mice treated with CLARI-AMIKA (2 weeks) or CLARI-AMIKA (4 weeks) (P Ͻ 0.01). The mean numbers of CFU in mice treated with CLARI-RBT did not differ significantly from those in mice treated with CLARI alone; those in mice treated with CLARI-EMB, with or without RBT, were significantly less in the lungs than the corresponding value in the lungs of mice treated with CLARI alone, whereas the mean number of CFU in the spleens did not differ significantly between the treatment groups.
Enumeration of CLARI-resistant mutants in spleens. As shown in Table 2 , no CLARI-resistant mutants were isolated at 4 weeks from the spleens of control mice when the total number of CFU was 10 7.57 Ϯ 10 0.59 per spleen. However, at 11 weeks, when the total number of CFU per spleen was greater than 10 8.0 , CLARI-resistant mutants were isolated from the spleens of most of the control mice, and the numbers of such mutants increased slightly between 11 and 16 weeks (P Ͻ 0.05).
As observed in previous studies (10, 12) , the frequency of CLARI-resistant mutants in an untreated bacterial population remained constant, between 1/10 7 and 1/10 8 , up to 20 weeks. After 16 weeks of treatment, CLARI-resistant mutants were isolated from the spleens of most of the mice that had been treated with CLARI alone in a proportion similar to that in which they were isolated from the spleens of untreated control mice (Table 2 ). However, because the total number of CFU had decreased significantly during the course of treatment (Table 1), the frequency of CLARI-resistant mutants was much greater in the bacterial population of mice that had been treated with CLARI alone than in that of the untreated control mice ( Table 2) , indicating that the mutants were selected during the course of monotherapy with CLARI.
As is also shown in Table 2 , CLARI-resistant mutants were isolated from the mice treated with all of the CLARI-containing combined regimens except for those treated with CLARI-AMIKA; no mutants were isolated from mice treated with CLARI-AMIKA (4 weeks) or CLARI-AMIKA (8 weeks), and mutants were isolated from only 20% of the mice that had been treated with CLARI-AMIKA (2 weeks), a proportion significantly smaller than that from the mice treated with CLARI alone (P Ͻ 0.01). Therefore, selection of the CLARIresistant mutants was reduced or prevented by the combination CLARI-AMIKA, whereas the proportions of spleens containing CLARI-resistant mutants and the mean numbers of CFU of the resistant mutants per spleen were not significantly smaller in the mice treated with CLARI-RBT, CLARI-EMB, or CLARI-EMB-RBT than in those treated with CLARI alone.
The MICs of CLARI for the resistant organisms isolated from the spleens of both control and treated mice determined on CLARI-containing 10% OADC-enriched 7H11 agar were Ն1,024 g/ml.
DISCUSSION
Although CLARI is by far the most important antimicrobial agent for the treatment of disseminated M. avium infection in AIDS patients (2) (3) (4) (5) , it displayed only a modest to a moderate degree of bactericidal activity against M. avium in mice even after 16 weeks of treatment (9, 10) . Moreover, in previous studies CLARI resistance developed rapidly in patients (3, 4) and in beige mice (9, 10) during monotherapy. Therefore, the identification of companion drugs that might both enhance the activity of CLARI-containing regimens and prevent the selection of organisms resistant to CLARI is urgently needed.
The results of the present study demonstrated that after 16 weeks of treatment all seven CLARI-containing regimens displayed a certain degree of bactericidal activity against M. avium. However, viable organisms were isolated from the spleens and lungs of all M. avium-infected beige mice even after treatment for 16 weeks with the most active regimens: CLARI-AMIKA (4 weeks) or CLARI-AMIKA (8 weeks) . This indicates that none of these regimens is as active against M. avium as the regimens currently used against M. tuberculosis (13) . Furthermore, because the bacterial population in patients with disseminated M. avium infection (18) is considerably larger than that in patients with tuberculosis, the duration of chemotherapy for disseminated M. avium infection in AIDS patients must be longer than that of treatment for tuberculosis and should be continued even after blood cultures have become negative.
Among the six CLARI-containing combined regimens studied, only the combinations CLARI-AMIKA (4 weeks) and CLARI-AMIKA (8 weeks) displayed significantly greater bactericidal activity in both spleens and lungs than CLARI alone, indicating that even CLARI in combination with an initial 4 weeks of AMIKA made a difference in the bactericidal activity of CLARI. An initial 2 weeks of treatment with AMIKA also showed a marginal effect in decreasing the CFU counts, whereas combining CLARI with RBT through the whole period of treatment was no more bactericidal than CLARI alone. As in our earlier experiments (10), CLARI-EMB with or without RBT appeared to be more active in the lungs but not in the spleens than CLARI alone; the significance of these findings remains obscure.
CLARI-resistant mutants were isolated from virtually all of the mice treated with CLARI alone, indicating that the mutants had already emerged in the majority of mice at 4 weeks, when the treatment was begun, but they were few in number (less than 10 0.94 CFU per spleen) ( Table 2 ). Among the groups treated with CLARI-containing combined regimens, multiplication of CLARI-resistant mutants was significantly reduced in the mice treated with CLARI-AMIKA (2 weeks), and their selection was prevented by treatment with CLARI-AMIKA (4 weeks) or CLARI-AMIKA (8 weeks), suggesting that 2 weeks of treatment with AMIKA killed the majority of the resistant mutants and 4 to 8 weeks of AMIKA completely killed the mutants. However, CLARI-resistant mutants were isolated from more or less the same proportion of the spleens, with almost the same number of CFU, of mice treated with CLARI-RBT, CLARI-EMB, and CLARI-EMB-RBT as the spleens of mice treated with CLARI alone, indicating that the activities of RBT, EMB, and EMB-RBT given for 16 weeks were so weak that they were unable to contain the multiplication of resistant mutants that started from a tiny number of resistant mutants.
Finally, because the population of M. avium in the spleens of AIDS patients with disseminated M. avium infection may be greater than 10 10 CFU/g (18) , whereas we found only about 10 8 CFU/g in the spleens of beige mice at the time that treatment was begun, it appears likely that the number of CLARI-resistant mutants in AIDS patients is more than 2 orders of magnitude greater than that in the beige mice. Therefore, with respect to the optimal duration of treatment with AMIKA, one should be extremely cautious in extrapolating the results from beige mice to AIDS patients. It may well be that 4 or 8 weeks of daily treatment with AMIKA may be insufficient to prevent completely the selection of CLARI-resistant mutants in AIDS patients. On the other hand, because AMIKA displayed a significant postantibiotic effect against the M. avium complex (1), it may be possible to administer the drug intermittently, thus reducing the toxicity associated with prolonged administration of the drug. Certainly, additional studies of the activities of different dosages, frequencies, and durations of administration of AMIKA in preventing the selection of CLARIresistant mutants in beige mice with advanced M. avium infections are required.
